September 23, 2014
ANN ARBOR, MICHIGAN, SEPTEMBER 23, 2014 (PR NEWSWIRE) -- Terumo Cardiovascular Group today announced that, beginning immediately, it will distribute Nonin Medical's SenSmart™ Model X-100 Universal Oximetry System to adult and pediatric cardiovascular hospitals in the United States. This is an expansion of the distribution agreement between Terumo and Nonin, which was originally entered into on May 1, 2013.
The Nonin SenSmart Universal Oximetry System is the first dedicated oximeter system that provides measurements of both regional oximetry (rSO2) and pulse oximetry (SpO2). The SenSmart system provides comprehensive monitoring of up to six-channels of rSO2 and SpO2 in an innovative side by side view. No other oximeter system provides more than four channels of monitoring. The signal processor is substantially smaller than previous versions, making the SenSmart system ideal for use in a variety of settings where space is an issue, such as the CVOR or ICU. The system allows anesthesiologists, perfusionists, cardiovascular surgeons and other clinicians to quickly identify tissue ischemia events before they become critical.
"We're excited to offer this next-generation monitoring device to our customers, particularly because the new features and upgrades are the direct result of customer feedback on the Nonin EQUANOX™ Model 7600 Regional Oximetry System," said Carol Koch, Senior Product Manager, Cardiovascular Monitoring. "Customers said they wanted features like an easier to use interface, color-coded and site-labelled display and smaller signal processors. The result is the SenSmart Model X-100 Universal Oximetry System, an intuitive and easy to use device that delivers both pulse and regional oximetry measurements today, and is designed to accommodate more parameters in the future."
Advantages of the SenSmart™ Model X-100 Universal Oximetry System include:
Terumo Cardiovascular Group manufactures and markets medical devices for cardiac and vascular surgery with an emphasis on cardiopulmonary bypass, intra-operative monitoring and vascular grafting. The company is headquartered in Ann Arbor, Michigan, with manufacturing operations in the U.S., Europe and Asia. It is one of several subsidiaries of Terumo Corporation of Japan that is focused exclusively on cardiac and vascular specialties. For more information, visit www.terumo-cvgroup.com.
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve.
Nonin Medical, Inc. invented the finger pulse oximeter and is a leader in designing and manufacturing noninvasive medical monitoring solutions that meet customers' technology needs today and tomorrow. Headquartered in Plymouth, Minnesota, USA, with an additional customer service center in Amsterdam, the Netherlands, Nonin Medical sells its pulse and regional oximeters, capnographs, sensors and software to health professionals and consumers in more than 125 countries. The company also has more than 200 OEM partners worldwide. For more information, visit www.nonin.com.
Terumo® is a trademark of Terumo Corporation. SenSmart™ and EQUANOX™ are trademarks of Nonin Medical, Inc. Philips®, IntelliVue®, VueLink® and IntelliBridge® are registered trademarks of Koninklijke Philips Electronics N.V. Bluetooth® is a registered trademark of Bluetooth SIG, Inc.
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.